中国肺癌杂志2017，Vol.20Issue(4)：287-292,6.DOI:10.3779/j.issn.1009-3419.2017.04.10
c-MET通路和抑制剂在非小细胞肺癌中的研究进展
Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer
摘要
Abstract
c-MET is considered a promising oncogenic driver in non-small cell lung cancer (NSCLC) after the discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK).MET activation including gene mutation,amplification and protein overexpression,all of these are potential therapeutic targets and are associated with poor prognosis.Clinical evidence suggests a role for MET activation as both a primary oncogenic driver in subsets of lung cancer,and as a secondary driver of acquired resistance to EGFR-tyrosine kinase inhibitor (TKI).This review focuses on the MET activation in NSCLC and the latest trials of its treatment.关键词
肺肿瘤/c-MET/扩增/克唑替尼Key words
Lung neoplasms/c-MET/Amplification/Crizotinib引用本文复制引用
俞晓晴..c-MET通路和抑制剂在非小细胞肺癌中的研究进展[J].中国肺癌杂志,2017,20(4):287-292,6.
